In short
The episode is a CNBC “Squawk Pod” segment focused on two big themes: (1) markets reacting to oil/geopolitics and (2) the “AI trade” dominating stocks and investment risk, plus a medical breakthrough. On oil, guests discuss falling WTI/Brent after a U.S.-Iran pause, but warn it’s not true normalization due to Red Sea disruptions (Houthis, Bab al-Mandeb traffic) and other flashpoints (Ukraine hitting Russian energy sites; mined straits). Halima Croft (RBC) argues oil is a “broken barometer” and that China’s reduced imports (down 4–5 million bpd) and inventory drawdowns muted price spikes. Steve Eisman (Real Eisman Playbook; ex-Neuberger Berman) claims “it’s all one trade” = AI; diversification is illusory because banks, bonds, and tech are tied to AI capex and financing. He warns that if AI fails, markets could face a major correction; he lightened Alphabet/Google exposure and is sitting in cash.
Notable examples
NVIDIA’s reported $250B backstop talks for OpenAI; Google stock drop tied to higher capex. The medical segment features Stanford neurologist Frank Longo (PharmaTrophic), promoting LM11A31/Compound 31: a pill targeting amyloid, tau toxicity, and inflammation, with Phase 2/2A evidence of slowed synaptic/network degeneration and Phase 3 readiness.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOMarket Insights on Oil Prices
0:36 to 0:59
Discussion on recent changes in oil prices and market sentiments.
“including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading.”
Market Insights on Oil Prices
2:21 to 4:23
Discussion on recent changes in oil prices and market sentiments.
“Stand Becky by in 3, 2, 1, cue it, please.”
Steve Eisman's AI Market Perspective
4:23 to 6:15
Steve Eisman shares views on AI's impact on market diversification.
“Halima's going to make the case that, you know, don't be complacent and don't think that it's over and don't think that the strait, if it does reopen, suddenly everything goes back to normal.”
Legal Perspectives on AI and Regulation
6:15 to 8:00
Discussion on the role of lawyers in AI and regulatory challenges.
“Yeah, Thursday, I think it must have been when he was on.”
Global Oil Market Dynamics
8:00 to 10:03
Analysis of global oil market conditions and geopolitical influences.
“Well, the pause is in and the war premium coming out.”
China's Role in Oil Supply
10:03 to 14:00
Exploration of China's influence on oil imports and global market prices.
“All right, Dan, just the feeling of what's been happening with the Red Sea, too.”
Market Dynamics and Chinese Oil Imports
14:00 to 20:23
Discussing the impact of Chinese oil imports and geopolitical factors on market balances.
“The fact that the Chinese made the decision to slash imports by four to five million barrels a day.”
Market Dynamics and Chinese Oil Imports
20:40 to 21:06
Discussing the impact of Chinese oil imports and geopolitical factors on market balances.
“an original podcast from Charles Schwab.”
Steve Eisman on AI Market Trends
21:40 to 28:00
Steve Eisman discusses the complexities of the AI market and its potential corrections.
“NVIDIA is in talks to provide a$250 billion backstop for OpenAI as part of a large data center project.”
The Impact of Market Dynamics
28:00 to 28:33
Discussion about the interconnectedness of various market factors and personal investment strategies.
“What scares me is that it's all one trade.”
Show all 25 chapters
Oil Prices and Economic Indicators
28:33 to 29:54
Examining the current state of oil prices and their effects on the economy.
“We talk all the time about the Middle East because you can say AI is driving everything, but you could also say oil prices are driving everything right now, too.”
AI's Influence on Market Trends
29:54 to 31:09
Exploring the role of AI in investment and market behavior amidst current economic conditions.
“But does the, for lack of a better term, the bubble popping, does it come from people slowing down on the build out or does it come with the promise of what it's supposed to do disappointing people?”
Personal Experiences with AI
31:09 to 32:21
A light-hearted conversation about the personal benefits gained from using AI technology in cooking.
“And I think that is a potential bottleneck.”
Upcoming Fed Meeting and Its Relevance
32:21 to 32:44
Discussion on the implications of the upcoming Federal Reserve meeting on market sentiment.
“I mean, look, if the Fed starts to raise rates very aggressively, that would be important.”
Upcoming Fed Meeting and Its Relevance
33:16 to 33:34
Discussion on the implications of the upcoming Federal Reserve meeting on market sentiment.
“One minute you're cruising in your RV, the next your tire hits a massive pothole.”
Introduction to Alzheimer's Drug
33:40 to 34:20
Transitioning to a discussion about a new Alzheimer's drug and its potential impacts.
“Not available in all states or situations.”
Understanding Compound 31
34:20 to 37:16
Dr. Frank Longo explains how their new drug approaches Alzheimer’s differently.
“You're listening to Squawk Pod from CNBC.”
The Amyloid Plaque Debate
37:16 to 38:10
Discussing the controversy surrounding amyloid plaques in Alzheimer's and their relationship to dementia.
“And Indiana University was able to say, hey, we know who was on the placebo, who was on the low dose, who was on the high dose based on what they saw.”
Genetic Resilience in Alzheimer's
38:10 to 39:11
Exploring genetic factors that contribute to resilience against Alzheimer's despite amyloid presence.
“But an amazing observation is there are people whose brains are filled with amyloid, even the toxic tau, and they don't get demented.”
Phase Three Trials for Compound 31
39:11 to 40:08
Updates on the progression and expectations for phase three trials of the new Alzheimer's drug.
“And then once we finished testing in mice, we wanted to move it to people.”
Potential Applications of Compound 31
40:08 to 41:03
Discussing the broader applications of the new drug across various neurological conditions.
“The existing treatments are intravenous or injection, and they do have some important side effects, brain swelling or brain hemorrhage.”
The Future of AI and Human Cognition
41:03 to 42:00
A philosophical discussion on AI, human cognition, and the complexities of the brain.
“That's where too much tau accumulates in the brain.”
Understanding the Brain's Blueprint
42:00 to 43:12
Explore the intricate relationship between genes and brain development.
“How about a genome that can have the blueprint to set up?”
Personal Journey into Neurology
43:12 to 43:51
Hear Dr. Longo's personal connection to neurology and childhood inspiration.
“Do you want to explain why you're a neurologist?”
Advancements in Rare Disease Treatments
43:51 to 44:08
Learn about ongoing clinical trials and the quest for drug development.
“We really appreciate your stopping by to talk to us about it.”
Transcript
Automatic transcript. May contain errors.0:00This is Stute calling about your overdue account balance. You owe$9 ,000,$17.86. How would you like to pay? That was the sound of Stute, the AI coworker that collects your cash for you. Stute's collecting over$200 million a month for its customers autonomously. Got cash stuck in overdue invoices? Get Stute and start collecting in days. Go to stute.ai, that's S-T-U-U-T.ai today. This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Join host Keith Lansford for this information-packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading.
0:49Download the latest episode and subscribe at schwab.com slash marketupdatepodcast or find Schwab Market Update wherever you get your podcasts. Bring in show music, please.
1:28And oil prices falling. Halima Croft on global energy. Do I think oil is a barometer for the pressure building in the Middle East? No, I think it's a broken barometer. The market's rise boosted by enthusiasm in one key technology. We turn to veteran Wall Street watcher Steve Eisman. Oh, I think it's all one trade. It's AI. Who is reducing his exposure to artificial intelligence, including trimming his stake in long-held stock Alphabet. What scares me is that it's all one tray, so it better succeed. Plus a pill to treat Alzheimer's. We think our drug is creating this resilience. Stanford neurologist Frank Longo on the breakthrough in clinical trials that he wants to get into patients.
2:13This is a drug right here. It's a pill. It can be taken orally. It is Monday, July 27th. Squawk Pod begins right now. Stand Becky by in 3, 2, 1, cue it, please. Good morning, everybody. Welcome to Squawk Box right here on CNBC. We are live from the Nasdaq market site in Times Square. I'm Becky Quick along with Joe Kernan. Andrew is off today. A third week in a row of declines for the Dow last week. But if you're looking at the Dow and the S &P 500, they're less than 3 % from all-time highs. It's the Nasdaq that people are watching a little more closely, the technology names there. The Nasdaq is more than 8 % from its all-time high.
2:54But the gains that we're seeing this morning soundly because of what we've seen with energy prices dropping rapidly over the course of the weekend. You'll see that at this point, if you check out WTI, it is down by close to 8%. 82.35 is the last trade for WTI. And, Joe, it's interesting. Last week, WTI was up by about 8.25%. So we've seen it give it all back over the course of this weekend, basically. I just had the, I don't know, the overall feeling that it seems heavy to me. And we'll have Halima Croft on it. We'll talk to her about it. I don't know what the spot price looks like. But the futures seem like even a glimmer of anything.
3:35And they immediately, we talked about it was the frog boiling. Because grudgingly going up, I mean, it was a kinetic war. There were, you know, forays back and forth every night, and it was going up like a dollar, a dollar, a dollar, a dollar. 13 days in a row, you have the United States launching a tax. Almost like resisting to go up. I think that the market might be well supplied or something. I don't know. We'll talk to Halima about it. But my feeling was, you know, it's ready to go back to 80 in just the drop of a hat, which it did. And it's all good for everything. I mean, I'm glad it's not 130 or something like that.
4:12But with the Red Sea involved now and the strait closed. With the Bouthis in Yemen, yeah, launching attacks on Saudi Arabia's flank, where they've been getting out. I think they've been getting out maybe 7 % of the daily oil usage through the Red Sea. Halima's going to make the case that, you know, don't be complacent and don't think that it's over and don't think that the strait, if it does reopen, suddenly everything goes back to normal. I don't know. No, it just seems maybe not heavy, but it just seems it's never gone where it could have gone. No, it seems like a risk off position where anytime talks open up, people think that this can change pretty rapidly for the better without those attacks taking place.
4:52And the future is kind of similar to they seem to want to go higher. But so many people think that it's the most expensive market that we've ever seen. And, you know, that that AI has inflated the bubble so much and it's so much like 1999. I think the hardest thing to do right now would be to buy at these levels. And if it's the hardest thing, that's usually the right thing. But let's talk about... Steve Eisman is going to join us today. He's going to talk a little bit about the AI trade. His point is that it's impossible to get diversification at this point because everything's an AI trade. Even the banks, he says, are AI trade at this point because they're doing so much financing for AI trade deals that are out there.
5:35So either it's going to be a huge win or everything's going to collapse. It's a it's a bilateral way of looking at all of these markets today, too. I read something. I shouldn't. And I shouldn't. I probably shouldn't voice my. But I read David Fox, who built like one of the largest law firms in the country now says A.I. is the is the profession's future. And I was just thinking, what if there were no lawyers? OK, can I just tell you? What if it was all A.I.? What a wonderful world. it would be. Except I had a conversation in the hallway with Walter Isaacson on Thursday after the show because we'd been talking about this idea.
6:17I'm sorry, was it Friday? Yeah, Thursday, I think it must have been when he was on. We had been talking on air about what you do with a situation like an open AI where its bot gets loose, it goes and hacks into places. How do you stop without regulatory oversight, which is going to be pretty hard to get anybody on agreement on regulatory oversight. How do you stop that kind of outrageous behavior and force the AI companies, the big, the big, you need lawyers to do that? Yeah. Basically he said, that's what you might be able to use. Why can't you use AI lawyers for? Because they're all over the place.
6:48Why can't you use AI lawyers to do it? You've bought to do it. Had another road trip, you know, six hour trip. Every billboard are the shyster personal injury types. And they all have different, They all have these parasites. They all have. Walter's point was maybe those parasites could do something useful for society. Well, that would be a switch. Yes. And I said, she goes, you know, a lot of people need those people and you need to advertise to get your name out. And I go, they have magnetic business cards as the ambulances are driving by. Call me, you know, hoping for another whatever that horrible.
7:27Walter's point was that they've been a little too aggressive down in New Orleans with some of the cases they've taken down there. But maybe they could do some good for society by trying to put clamps on AI. See, I really wish I hadn't gone down this path at all. I'm going to hear from some of these people. In fact, they might sue me for saying these things because they are looking for a reason. And a pause in fighting between the United States and Iran. That's what we've been talking about this morning. It's reflected in the price of oil. So our Dan Murphy joins us right now with more from Abu Dhabi.
7:59And Dan, what's the feeling on the ground there? Becky, Joe, good morning. Well, the pause is in and the war premium coming out. As you've just flagged, a huge reversal for Brent right now and oil prices pulling lower. There have been no U.S. strikes on Iran since Thursday night, crude on a heavy rollback as a result. And Brent's actually snapping what was a three-week rally after trading above 100 USD last week. Analysts at ING putting it pretty plainly this morning, saying the price action in oil this morning clearly reflects the market's desperation for positive news. ING also calling this the first tangible signal of de-escalation.
8:39Now, we don't know what prompted this halt or how long it might last. The U.S. ambassador to the U.N., Mike Wald, speaking to Fox News at the weekend, saying President Trump has paused attacks on Iran to give diplomacy more time. At the same time, Axios reports today that CENTCOM's own commander, Admiral Brad Cooper, told the White House that 13 rounds of strikes had reached the limit of what U.S. airpower could achieve. His message to Trump was either return to full war or stop. And President Trump has chosen to stop. At the same time, Yemen's Houthis claim they struck Saudi oil facilities on the Red Sea coast.
9:17Aramco and the Saudi energy ministry have not commented yet. And traffic through Bab al-Mandeb fell again on Sunday, according to Kepler data. And there's a third supply risk that's emerging as well. Ukraine saying it hit several Russian oil sites and an Iranian merchant vessel in the Caspian. Iran says one sailor was killed and is now demanding a U.S. response, a U.N. response, I should say. So the next signal that we're watching is actually going to come from Washington. Benjamin Netanyahu and Vladimir Zelensky due to meet President Trump tomorrow. So for oil, the question is whether this pause becomes a real de-escalation moment or whether any one of these flashpoints puts that war premium straight back in the price.
10:01With that, it's back over to you. All right, Dan, just the feeling of what's been happening with the Red Sea, too. How has that changed the feeling on the ground just with the renewed tax on some of the U.S. allies at this point? Well, we're trying to get clarity on exactly what's happening inside the Bab el-Mandeb right now. For weeks, for months, in fact, we've been talking about the block inside the Strait of Hormuz. Obviously, that's been material for oil prices. But at the same time, the Houthis have been threatening vessels inside that critical Red Sea waterway. It means oil out of Saudi Arabia either has to move south and attempt to pass through the Bab al-Mandeb or alternatively move north through the Suez Canal.
10:45Shipments, according to Kepler data that I've been monitoring, have been pretty slow at this point. So it seems as if there is a hesitation on the ground to actually get those ships moving. And of course, moving through the Suez instead of going through Bab al-Mandeb, of course, adds to the time and adds to the cost. So there's an extra impetus there to not make that journey. All of that should be a catalyst for a higher oil price, but that's not necessarily happening right now. The mood on the ground here, I can say, is one of cautious optimism right now. Obviously, the market's certainly taking this pause in their stride right now.
11:21We're watching and waiting to see exactly what happens next and whether or not we will see a resumption of hostilities. I think the real signal is exactly what we see coming out of the meeting between Trump and Netanyahu this week. If the Israelis push the U.S. to try and perhaps return to the conflict here to ensure that Iran can never have a nuclear weapon and to maybe end this once and for all. Or if the president decides to do what he has done now and continue to put the brakes on and push for a diplomatic track. Either way, market's watching very closely to see which way this goes next. All right, Dan, thank you very much.
11:59It's good to see you this morning. Meanwhile, U.N. Ambassador Mike Waltz gave a round of interviews at a Sunday news shows and addressed reports the U.S. is running low on air defenses in the Middle East. The U.S. military, and I've verified this every which way, has everything that it needs to conduct this campaign as effectively as it needs to be. And I have to tell you, the people that are leaking this nonsense deserve to be in jail. NBC News reporting late last week that the military is letting some attacks through in order to preserve weapons that are used to intercept incoming projectiles.
12:42Joining us now is Halima Croft, Global Head of Commodity Strategy at RBC Capital Markets and a CNBC contributor. Halima, I was talking about just trying to summarize your overall feelings that, you know, don't get too complacent here about a pause because it's still going to be a while before anything normalizes. But then I was making the point that it just seems like we're fairly well supplied because the minute you get any indication of a pause. It seems like the bottom drops out. It took a long time, 13 trading days to get back from 68 or 69 back up to where we were up near 90. Why does the market seem like it doesn't want to go to 120?
13:31Because in the old days, if you even said there's a possibility the straight's going to be closed, you'd go to 140 or something like that. Why isn't it like that? is that basically a lot of people in the market are still pricing endgame. And so anytime you have a pause, then we move to how quickly can we get ships moving through the straight-to-form moves. So I do think we're getting ahead of ourselves in terms of normalization. But when you bring up the issue of being well-supplied, I think the China factor is still so paramount. The fact that the Chinese made the decision to slash imports by four to five million barrels a day.
14:08Like that was really consequential in terms of market balances. Now, we also really did run down our reserves. Our inventories have really been run down. But the China factor, I think, has been really critical in terms of why we're not at 200, despite the fact that we have very little traffic through Strait of Hormuz. Now we have issues in the Red Sea and Ukraine is still hitting Russian energy targets. Because the futures, they should be reflecting your fears and your angst, I think, because it's not going to be easy. Right. What's spot right now? Approximately. What are people paying? What's the highest people are paying anywhere right now?
14:49Well, I think the key thing is, like, if you're China, we did see them, like, really starting to try to source Russian barrels again. Because if you're trying to actually buy the barrel, that's different than the price that you see on the screen. And one thing I'll tell you early on in this conflict, like, we heard from Middle Eastern national oil companies that in March, you know, Asian customers were paying$175 for their barrels. Now, so there was always this discrepancy. The key factor, though, is going to be, Joe, as we get into fall, do we see any type of normalization in terms of flows? And does China come back as a buyer into the market?
15:25If there's another formal ceasefire that they say, and who knows how long it lasts or what Iran does, is 70, are we headed back there near term? So again, are we going to have this kind of stalemate where you have these periodic two weeks of bombing, ships attacked? Then we have a pause. Does the pause turn into something that's durable? I mean, we also have to get the mines just cleared out of the strait. I mean, we talk about the attacks on actual vessels. The middle corridor of the strait is pretty heavily mined. And so, again, to get this key transit point open is going to take a while. We certainly need to see a stable security environment.
16:08I mean, there have been times through this whole conflict where people that market watchers are actually saying that oil is getting it wrong. It's like it's funny when when people do that. I don't I don't know how well they understand markets, but there are times where they say, well, it's obvious that I think they attribute it to individual traders or something, not the collective wisdom of of of of the marketplace. Has oil been been right about things? Or I think in your view, you think oil is is underestimating the true risk of the conflict staying. Do I think oil is a barometer for the pressure building in the Middle East?
16:51No, I think it's a broken barometer. But again, if China is going to scale back their imports by four to five million barrels a day, that plays a big role in terms of balancing the market, as well as running down our inventory buffers. So again, what are we looking for oil to tell us? Are we looking for oil to tell us how stable the security situation is? I don't think oil is a leading indicator of how stable the security environment is in the Middle East when you have essentially China becoming. China's now the swing consumer. So when China decides they're going to pare back their imports and we can run down our reserves, like that allows us to get through a crisis for that$200 oil.
17:32It doesn't mean, though, yeah. People that know what they're doing should have been should have been factoring in what China, I mean, it's a global marketplace. If that's what was going to happen, we should have known that. Were you predicting much higher prices or something? Is that why you're you're you keep saying, well, if it wasn't for China, then I would have been right. Is that where this is coming from? No, I think you have to be humble a little bit and saying, like, what did you not anticipate? And certainly we thought the scale of the disruption was so much bigger than we saw in Russia, Ukraine.
18:02And we should have been at those price points. But again, like if China is going to change our purchasing policy, if we are going to run down our reserves, I mean, I do think you end up in a different place. Again, if you ask me what I did not anticipate at the start of the conflict, I did not anticipate China playing such a big swing factor in terms of scaling back imports. So, again, it's a little bit of humility in terms of where the market is right now. Where did we get in at the beginning of the Ukraine war? What was the peak? I mean, we took out like$128. And so we never got close to that in terms of Brent pricing.
18:41And again, we never had a significant supply disruption in Russia, Ukraine. That was driven by a fear of a three million barrel a day disruption. You know, at one point during this war, we had over 10 million barrels being disrupted out of Hormuz. So the scale of the disruption was much larger this time around. It's still much larger, but the price response has been more muted. So, again, I think we have to look at other factors in the market. That's what's weird. You expect these futures to go absolutely crazy. And your point is that it didn't happen because of China. So we're going to take that to the bank because, I don't know, 80 just seems like the market must be wrong or something.
19:25Anyway, Halima, thank you. Thank you. Cheese will be next. Coming up on Squawk Pod, investor Steve Eisman, made famous by the bets he made in 2008, immortalized in the big short. He's not shorting the market now, but he's being cautious about big tech's reliance on artificial intelligence. So if this is a binary situation where AI succeeds and the market continues to push higher and higher, what happens if AI doesn't succeed? I think we have a big correction. How big? Now that's a hard question. Eisman's take on this AI everything market right after this break.
20:06Adventures don't always go as planned. One minute you're cruising in your RV, the next your tire hits a massive pothole. Progressive is ready for you when the unexpected hits with excellent claim service for your boat, RV, and motorcycle. Plus optional coverage like roadside assistance and on-the-water towing. Visit Progressive.com and make sure your next adventure is unforgettable for the right reasons. Progressive Casualty Insurance Company and Affiliates. Not available in all states or situations. Coverage is subject to policy terms and limits. This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab.
20:42Join host Keith Lansford for this information-packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com slash market update podcast or find Schwab Market Update wherever you get your podcasts. Ever finish your to-do list just in time for three more things to get added? That's what managing technology can feel like. There's always another ticket, another update, another thing demanding attention. That's why CDW's here.
21:17We help run, optimize, and evolve complex IT environments so your team can focus on moving the business forward. We've been there and solved that. When operations stop getting in the way, it's actually pretty amazing. We configure, optimize, and deliver the tech that runs business. CDW. Make amazing happen.
21:38This is Squawk Pod. Stand by Joe. Here's Mike. You're watching Squawk Box on CNBC. I'm Joe Kern along with Becky Quick. NVIDIA is in talks to provide a$250 billion backstop for OpenAI as part of a large data center project. There's a Wall Street Journal report that says that it guarantees from NVIDIA would help OpenAI lease a 10 gigawatt project in southern Ohio that's being developed by a soft bank subsidiary. And NVIDIA's backing will help the data center developer raise debt at more favorable terms than it could without a financial backer. And since it's not rated, since OpenAI doesn't have an investment grade credit rating as an unprofitable private company, terms have not been finalized and the deal could still fall apart.
22:29Anthropic, Microsoft, and Alphabet have also expressed interest in the site. And joining us right now to talk about what's really moving the markets is Steve Eisman. He is the host of The Real Eisman Playbook podcast and former senior portfolio manager at Neuberger Berman, obviously somebody who understands when markets get inflated at times and has done very well by poking holes in some of those things in the past. Steve, we've got a Fed meeting that's happening this week. We've got the busiest week of earnings. But you're really looking at this as an all-AI market at this point. Oh, I think it's all one trade.
23:06It's AI. Either it'll succeed or it won't. But I mean, I just take, for example, you know, the investment banks well reported. The numbers were really great. But, you know, why were they great? They were great because they're doing a lot of AI financing. So it's not like, you know, if you bought Goldman Sachs, you're diversifying your portfolio away from AI. I think the biggest news is that a year, if we were sitting here literally a year ago, the entire debate on AI would be, it's all great, rah, rah, let's spend money. Every time one of the companies would increase their capital expenditures, the stock would go up.
23:43It's much more complicated now. That doesn't mean it's all negative, but it's much more complicated. So you've got, it's become very capital intensive. It's questionable whether any of the LLM models have any moats around their businesses. And the Chinese AI models are a lot cheaper. So is there going to be a price war? I don't know the answer to a lot of those questions, but I don't think anybody else does either. And that's why, you know, for example, last week when Google reported the stock went down. Not because they didn't beat expectations. It's not because there was huge demand still coming through.
24:24But they increased the capex from$190 billion to$205 billion. People are freaking out. You know, we were asking the question earlier today, what would happen if some of those big hyperscalers actually cut their capex? How would the market react to that? I think the market would go straight down. I think so, too. To me, it's your damned if you do, damned if you don't situation almost. I mean, in the end of the day, it all boils down, in a sense, to NVIDIA. NVIDIA, I think when they reported last quarter, had 85 percent revenue growth. So if the hyperscalers cut, it wouldn't be 85 percent. And, you know, maybe that would be healthy for the long term.
25:06But I think the market would go straight down on that news. There's the front page story today in The Wall Street Journal that says NVIDIA is in talks to back open AI on a$250 billion financing, basically. for a data hub that could wind up costing half a trillion dollars in the long run on some of these things. NVIDIA has been involved with backing a lot of these deals. And if you ask Jensen Wang why, he would say because they are looking for the bottlenecks that are preventing AI from moving forward and they want to make sure they clear those bottlenecks. It's a sound strategy, but what do you think as somebody who watches the markets in terms of what this means?
25:44Look, I have questions about the health of Anthropik and OpenAI long term. I mean, this is great for NVIDIA long term, but Anthropik and OpenAI, the cost of their models is about five times more than Chinese models. So I think one of the bottlenecks is what's the future health of Anthropik and OpenAI in the face of models that are much cheaper? I don't know the answer to that question, but I don't think anybody else does either. Why are Chinese models so much cheaper? Because they're open source. And anthropic and open AI are closed source. And for whatever reason, the closed source models are just much more expensive.
Read the full transcript
26:26So what do you do overall? It's more complicated, but you wouldn't necessarily short this market at this point, would you? I would not. I've lightened up. I've taken, you know, I'll give you an example. I sold my Google a couple of months ago. I've owned Google. I can't even tell you how long I've owned Google. But I felt I wanted to reduce my exposure to AI. I haven't bought anything to replace it because, you know, buying something defensive or stapely is kind of a waste of time. Why? It doesn't go up. They don't go up. You know, people either want to buy AI or they don't want to buy AI. But they don't want to shift out of it to buy Clorox.
27:11So if this is a binary situation where AI succeeds and the market continues to push higher and higher, what happens if AI doesn't succeed? I think we have a big correction. How big? Now that's a hard question. I don't know. But, I mean, it's all one trade. It's literally one trade. I mean, even people who think they're diversified because they own 60 percent stocks and 40 percent bonds are missing the fact that they're actually not diversified because of their 60 percent. More than 50 percent of it is tech and AI related. And of the 40 percent of bonds, most of the new issuance of bonds is AI related.
27:58So even people who think they're diversified because they own bonds are not really that diversified. What scares me is that it's all one trade. So it better succeed. What are you doing if you've sold Google? I mean, if you sold Alphabet, what else have you done? I'm just sitting in cash. You just have a lot more cash? Until I can try and figure out what to do. What would it take to get you to deploy that cash? I don't know yet. I really don't. I mean, I don't think this debate's going to get settled within the next two weeks. We talk all the time about the Middle East because you can say AI is driving everything, but you could also say oil prices are driving everything right now, too.
28:42Oil prices are down 8 percent. You see the markets up. Right. Significantly. How much does that factor into it to tariffs factor into it? I think it factors it to a degree. I don't think this war is going to be over anytime soon. I don't think, I mean, I think President Trump wants the Iranians to give up their nuclear fuel, and the Iranians are not going to give up their nuclear fuel. So I don't think there's much to talk about. So, you know, we get these lulls, but then it doesn't do anything. But you're not worried about oil prices at this point? I think actually there's an oversupply. Yeah.
29:18That's why the Halima, who was a guest on my show, too, you know, pointed out that China has basically stopped buying oil, which is why oil prices haven't gone up that much. You would have thought oil prices would be$150 at this point, but they're not because there's actually an overproduction. And I also think some of these pipelines that are going to be able to avoid the straight are pretty close to being finished. Yeah, next year, I think maybe 2027 is when you hear from that. And that's why oil prices, I'm not really all that worried about oil prices. I mean, AI is going to be something. I'm like you, I'm not sure what.
29:58But does the, for lack of a better term, the bubble popping, does it come from people slowing down on the build out or does it come with the promise of what it's supposed to do disappointing people? I don't necessarily think the latter. It's going to be amazing. It's going to be something, something really good. That doesn't mean that everybody succeeds. that doesn't mean that these circular deals the latest nvidia deal like you gotta read it and it's like they're gonna you know back this but then they're gonna provide money for opening eye to buy their chips and it's so uh incestuous it's convoluted it's totally convoluted you don't know if there's any you know you don't know if there's any real profitability in any of of the machinations that you eventually there probably is for nvidia who was saying probably well there Yes, for NVIDIA.
30:58They're not doing it for free. But look, again, I think one of the bottlenecks is that Anthropic and AI, an open AI, are responsible for a lot of the spending that people are doing. And Anthropic and AI have models that are now much more expensive than the competition. And I think that is a potential bottleneck. I'm a much better cook because of AI. You are? Yes. And griller. Okay. When I grill things on, I'm much better. I mean, far better. Everything is juicier, tastes better. I do it a totally different way. I'm using the grill that has different zones. And you don't pay anybody for any of that.
31:37No, I use just open. The free stuff. I don't pay for it. Oh, you're free. Right. But he's very, very nice to me. Because you've beaten him into submission. Maybe so. No, Claude is like, so how was your, you know, how was your boneless breasted chicken? It was unbelievable, Claude. Thanks. It was any time. I kind of like that stuff. Very friendly. Steve, we've got a Fed meeting this week, too. You basically think that's just noise. Completely irrelevant. I mean, look, if inflation gets worse, they'll raise rates. And if inflation gets better, they'll cut rates. And so I don't understand why people get so exercised about it.
32:18Doesn't make much difference to you one way or the other. Not really. I mean, look, if the Fed starts to raise rates very aggressively, that would be important. But I don't see that. So, you know, it's good to talk about on television, but it doesn't really interest me that much. Steve, thank you for joining us today. It's good to see you. Thank you. Still to come, a potential game changer for the millions of Americans impacted by Alzheimer's disease. Stanford neurologist Frank Longo has spent decades developing a pill to counteract the worst of the brain degeneration. The problem with Alzheimer's is we're losing the synaptic connections between the neurons.
32:56Getting this potential drug to patients, next on Squawk Pod. I want to grow the game of soccer and give every kid the chance to play. What would you like the power to do? Bank of America champion street soccer advocate Kyle Martino and is proud to be the official bank of U.S. Soccer and FIFA World Cup 2026. Bank of America and A member FDIC. Adventures don't always go as planned. One minute you're cruising in your RV, the next your tire hits a massive pothole. Progressive is ready for you when the unexpected hits with excellent claim service for your boat, RV, and motorcycle. Plus optional coverage like roadside assistance and on-the-water towing.
33:34Visit Progressive.com and make sure your next adventure is unforgettable for the right reasons. Progressive Casualty Insurance Company and Affiliates. Not available in all states or situations. Coverage is subject to policy terms and limits.
34:09schwab.com slash market update podcast or find Schwab Market Update wherever you get your podcasts.
34:19Welcome back. You're listening to Squawk Pod from CNBC. Up and Becky, cue. More than 7 million Americans are living with Alzheimer's disease. And while there are treatments on the market, there is currently no cure. One new drug currently in clinical trials is offering hope for many, though. It is called LM11A31 or Compound 31, and it approaches treatment very differently from existing Alzheimer's therapies. Joining us right now to talk about it is Dr. Frank Longo. He's a Stanford University professor who actually headed up the neurology department there for 18 years. He's also the co-founder of Pharmatrophics.
34:57That's the company that has created this new drug. Dr. Longo, thank you for being with us this morning. It's good to see you. It's great to be here. Let's talk a little bit about how this drug is different from what exists on the market today, those drugs that try and target amyloid plaques. Right. So the drug's different in a number of ways. So the problem with Alzheimer's is we're losing the synaptic connections between the neurons. And there are multiple forces causing those connections to degenerate. There's the amyloid that accumulates in the brain. There are toxic forms of the tau protein or damages the synapses and inflammation.
35:32And on the market today, there are drugs that go after the amyloid, but not the other two. And so our drug deals with all three. So that's how it's different. You don't think the amyloid drugs are all that effective at this point? Well, they're an important start. I mean, they help a little bit, but they slow the loss of cognition by just a small amount. So it's a good start, but we need something much more powerful. You've completed phase two and phase 2A trials. What did compound 31 show in those trials? Sure. In the phase 2H trials in mild to moderate Alzheimer patients, we did brain scans.
36:09We did spinal taps. We did blood tests. So we looked at those patients very thoroughly. And all three of those measures indicate that we significantly slowed down the degeneration of the brain. We slowed down the loss of those synaptic connections. So we're very excited about that. How many patients were involved in that study? About 240. So we had about 80 on placebo, 80 on a low dose, and about 80 on a higher dose. You also sent the results of that study out to Indiana University to confirm what you had found. I think we're looking at some graphics of what you found on that. Why don't you talk us through what we're looking at?
36:44Sure. We took one of the forms of brain scans from that trial, and we coded the data so the Indiana University group would be blinded. And they have a new technique where they can measure network function in the brains of the patients in our trial. And what they found was that there was not much effect on the placebo group, but in the patients on the drug, they're able to reverse the degeneration of the networks. And what that image is showing in red is where we're gaining function of the network and the connections that are lost in Alzheimer's. The red is actually showing the drug effect, reversing that loss versus the placebo.
37:20And Indiana University was able to say, hey, we know who was on the placebo, who was on the low dose, who was on the high dose based on what they saw. And we're excited about that because it's an independent group that was blinded to the data. The age old question is whether amyloid plaques actually cause Alzheimer's or result from what's happening with Alzheimer's. And we still don't know. And if you found a family that has amyloid plaques everywhere but doesn't get dementia, that strongly argues that it's not necessarily just stopping amyloid plaques that would cure all symptoms. That remains a controversial question in the field.
38:03How much is amyloid contributing? I think most people think it's at least one important contributor. I think it's one important contributor. But an amazing observation is there are people whose brains are filled with amyloid, even the toxic tau, and they don't get demented. They live into their 70s and 80s. And their synapses are what, they're still intact. That's what seems to be the key. Exactly. The key word there is resilience. We call that resilience. And we think our drug is creating this resilience, is tapped into this resilience mechanism. And it's based somewhat on some gene that is either mutated in this family or this line of family in Columbia or something?
38:45Right. There's a family in Columbia that has a very strong gene that if you have that mutated gene, you for sure will get Alzheimer's. And there was a patient, those families generally have dementia starting at about age 40. And there was a patient there who made it into his 70s. He's perfectly well. His brain was filled with amyloid. and he's demonstrating resilience. Now he's lucky that he had resilience and the goal with our drug is so that everyone can be resilient. How did you come up with this drug to begin with? I know this was 20 years in the making. Yeah well this this drug has been a 20-year journey and the started off in my academic labs you know supported by funding from the NIH, the Alzheimer's Association, the Alzheimer Drug Development Foundation, the Estee Lauder family that started that here in New York.
39:30And then once we finished testing in mice, we wanted to move it to people. So my wife, Anne Longo, and I started our company, PharmaTrophic. She's a co-founder and the initial CEO. And we started the company to do the clinical trials and manage the commercial development. And so that's how we've done the human trials. The phase three trials can cost millions and millions, maybe hundreds of millions of dollars. Where do you stand right now with a phase three trial at this point. Right. Well, where we stand with the phase three trial, we're ready to go. We scaled up production of the drug. So we have enough drugs to do a phase three trial.
40:07This is the drug right here. It's a pill. It can be taken orally. The existing treatments are intravenous or injection, and they do have some important side effects, brain swelling or brain hemorrhage. This drug doesn't cause either one of those side effects and it can be taken orally. So we think this will be accessible to a lot more people. So this is the medication. We've scaled up production. So we think once we have the funding, we can enroll the first patients within about six months. Wow. The interesting part about this is you have done these studies with Alzheimer's, but you think that drug can work in a lot of other applications, including traumatic brain injury, Huntington's disease.
40:50I want to say Lewy body disease, Lewy body Parkinson's too. Yeah, this drug, because it makes the synapses resilient, and that's the key word here, resilience, it's a fundamental mechanism that can be applied to a number of brain disorders. So, for example, there's a rarer form of dementia called progressive supranuclear palsy, or PSP. That's where too much tau accumulates in the brain. Patients will start enrolling in a trial of taking this drug this summer. The NIH is funding that trial, and this drug was selected for that trial. They'll be enrolling this summer. So 86 billion neurons in the brain, supposedly.
41:28Hundreds of trillions of synapses. So AI, when do we get sentient AI? Is it ever possible when you think about that? With that many synapses, I think you can compete well with AI. That's human AI right there. I mean, we see green and smell perfume and have memories and feelings. And I mean, it's all mediated by synapses. It is. I'm a neurologist. I'm biased for the human brain. How about a genome that can have the blueprint to set up? I mean, how mind-boggling is that? Almost godlike. Yes, yes. I mean, we're still in the early days of understanding how the genome translates into setting up the brain and how all this wire and forms.
42:22I mean, a lot of it is obviously as things are happening, it's developing. Right, right. It's feedback that does it, but there must be an unbelievable blueprint to start with. I think there is an unbelievable blueprint, and I think that's why the basic science remains important. That's what's helping us figure out how we get from genes to this beautiful organ in our body. The basic science is telling us. We need a combination of the basic science and then translating and then good human trials. It's also binary. Everything that happens somehow is just that either the neuron either fires or it doesn't fire.
42:55Right. Yeah. Yeah. That's one or the other. Well, we can we can modulate those connections. So when you learn something, you're making the synaptic connection stronger than it was before you learned that. So it's why it's important to keep learning things. Dr. Longo, very quickly, I know that you got into this because of a very personal reason. Do you want to explain why you're a neurologist? Sure. I've been interested in the brain since I was a child. I have a sister. My sister, Patty, was one year younger than me. And she was born prematurely and suffered brain damage at birth. It's called cerebral palsy.
43:26And so she's cognitively impaired. And she was in a wheelchair. So as a child, I went to the doctor visits that my mother was taking her to. And I asked why the doctors couldn't make my sister, Patty, walk. And my mother, who was a nurse and therefore a medical authority, said, you can't fix the brain. There are no treatments for the brain. And that just stuck with me. So when I got to medical school, I looked for mentors that would help me train in how to make treatments for the brain. And that's what I'm still doing. It's very exciting work. We really appreciate your stopping by to talk to us about it.
43:57And we'd love to hear more about your progress with this drug too. Well, thank you. It's my pleasure. And we're looking forward to getting this phase three trial going. We want to get this drug to patients. Dr. Longo, thank you. And by the way, folks, for a deeper dive on everything happening in the rare disease space, you can visit CNBC.com slash cures. And there you can join thousands of people by signing up for the CNBC Cures newsletter to sign up for the latest in the rare disease community. Alzheimer's is not rare, but this drug could work on some rare diseases potentially as well. It definitely could.
44:29We should mention here that you can see video of our segments on CNBC's website. Head to CNBC.com slash cures to see Dr. Longo's Alzheimer's pill right there, as well as images of brain scans from PharmaTrophic's clinical trials. And that is Squawk Pod for today. We've come to the end. Squawk Box is hosted by Joe Kernan, Becky Quick, and Andrew Ross Sorkin. Tune in weekday mornings on CNBC at 6 Eastern to get the smartest takes and analysis from our TV show right into your ears. Follow Squawk Pod wherever you get your podcasts. We'll meet you right back here tomorrow. We are clear. Thanks, guys.
45:32decisions and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com slash market update podcast or find Schwab market update wherever you get your podcasts.
From the publisher
Nvidia is in talks with OpenAI to finance a new data center project in Ohio, according to reports. As markets kick off the busiest week of earnings season, investor Steve Eisman shares his perspective on the AI trade, big tech’s big capital expenditures, the moats around tech and AI companies, and how he’s hedging his own portfolio. CNBC’s Dan Murphy reports on the current pause in fighting between the U.S. and Iran, and RBC Capital Markets’ Helima Croft discusses the conflict’s impact on the energy markets. Plus, PharmatrophiX co-founder and Stanford Professor Dr. Frank Longo explains Compound 31, a new FDA-approved drug to treat Alzheimer’s. He shares his personal journey toward medical innovation in the field, and shares the differentiators between Compound 31 and the Alzheimer’s treatments that have come before it.
Dan Murphy - 07:50
Helima Croft - 12:43
Steve Eisman - 22:36
Dr. Frank Longo - 34:43
In this episode:
Joe Kernen, @JoeSquawk
Becky Quick, @BeckyQuick
Dan Murphy, @dan_murphy
Katie Kramer, @Kramer_Katie
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

